APA (7th ed.) Citation

Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, & Chen C. (2018). Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. Dove Medical Press.

Chicago Style (17th ed.) Citation

Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, and Chen C. Budget Impact Analysis of Sarilumab for the Treatment of Rheumatoid Arthritis in Patients with an Inadequate Response to Conventional Synthetic DMARD or TNF Inhibitor Therapies. Dove Medical Press, 2018.

MLA (9th ed.) Citation

Ferrufino CP, et al. Budget Impact Analysis of Sarilumab for the Treatment of Rheumatoid Arthritis in Patients with an Inadequate Response to Conventional Synthetic DMARD or TNF Inhibitor Therapies. Dove Medical Press, 2018.